We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

70 hedge funds and large institutions have $117M invested in BioXcel Therapeutics in 2020 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 8

85% more capital invested

Capital invested by funds: $63.3M → $117M (+$53.5M)

63% more funds holding

Funds holding: 43 → 70 (+27)

0.36% more ownership

Funds ownership: 1.5% → 1.86% (+0.36%)

6% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 17

7% less call options, than puts

Call options by funds: $4.06M | Put options by funds: $4.36M

Holders
70
Holders Change
+27
Holders Change %
+62.79%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
36
Increased
16
Reduced
17
Closed
8
Calls
$4.06M
Puts
$4.36M
Net Calls
-$303K
Net Calls Change
-$303K

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$12M
2
ACP
Acuta Capital Partners
California
+$7.08M
3
DCM
Driehaus Capital Management
Illinois
+$6.74M
4
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$6.16M
5
APM
Avidity Partners Management
Texas
+$4.74M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.85M
2
AIM
Artemis Investment Management
United Kingdom
-$6.44M
3
California Public Employees Retirement System
California Public Employees Retirement System
California
-$4.77M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.73M
5
DAM
DLD Asset Management
New York
-$956K
Name Holding Trade Value Shares
Change 		Change in
Stake
HP
26
Hound Partners
New York
$782K +$786K +2,188 New
LCM
27
Laurion Capital Management
New York
$671K +$674K +1,875 New
CBA
28
Coastal Bridge Advisors
Connecticut
$559K +$562K +1,563 New
BBVA
29
Banco Bilbao Vizcaya Argentaria
Spain
$477K -$643K -1,790 -57%
KCM
30
Knoll Capital Management
Florida
$447K +$449K +1,250 New
Russell Investments Group
31
Russell Investments Group
United Kingdom
$440K +$441K +1,226 New
Deutsche Bank
32
Deutsche Bank
Germany
$349K -$719 -2 -0.2%
Charles Schwab
33
Charles Schwab
California
$341K +$3.23K +9 +1%
AQR Capital Management
34
AQR Capital Management
Connecticut
$340K +$342K +952 New
Squarepoint
35
Squarepoint
New York
$322K -$196K -544 -38%
CIAS
36
Capital Investment Advisory Services
North Carolina
$320K +$321K +894 New
SO
37
STRS Ohio
Ohio
$281K +$92.4K +257 +48%
AllianceBernstein
38
AllianceBernstein
Tennessee
$275K +$276K +769 New
Creative Planning
39
Creative Planning
Kansas
$244K -$88.4K -246 -27%
Jane Street
40
Jane Street
New York
$239K +$240K +669 New
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$239K +$240K +669 New
HAG
42
HighPoint Advisor Group
Illinois
$236K +$173K +480 New
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$225K +$18K +50 +9%
Wells Fargo
44
Wells Fargo
California
$184K -$192K -533 -51%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$141K -$65.1K -181 -31%
DCM
46
DAFNA Capital Management
California
$103K +$104K +288 New
CG
47
Cutler Group
California
$103K +$104K +289 New
Morgan Stanley
48
Morgan Stanley
New York
$100K -$129K -359 -56%
AIG
49
American International Group
New York
$92K -$5.39K -15 -6%
Victory Capital Management
50
Victory Capital Management
Texas
$84K +$84.1K +234 New
1
2
3 4

BTAI Hedge Fund Activity: Q1 2020 in Review

70 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2020, worth a combined $117M — up 85% from $63.3M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new BTAI positions and 8 closed out — a net gain of 28 holders — while 16 added to existing stakes and 17 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $12M. The largest seller was Fidelity Investments, cutting an estimated $6.85M.

  • 70 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2020, up from 43 in Q4 2019.
  • Funds reported $117M of BioXcel Therapeutics stock for Q1 2020, up 85% quarter-over-quarter.
  • 36 funds opened new BioXcel Therapeutics positions in Q1 2020 and 8 closed out, a net change of +28 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2020 was Ikarian Capital, an estimated $12M added.
  • The largest BioXcel Therapeutics seller in Q1 2020 was Fidelity Investments, an estimated $6.85M sold.

Based on aggregated 13F filings for Q1 2020.